# Material Change Report

## Section 75(2) of the Securities Act (Ontario)
## Section 118(1) of the Securities Act (Alberta)
## Section 85(1) of the Securities Act (British Columbia)

### 1. Reporting Issuer

CME Telemetrix Inc.
560 Parkside Drive
Waterloo, Ontario
N2L 5Z4

### 2. Date of Material Change

December 1, 2003

### 3. Press Release

A press release in respect of this material change was issued through Canada Newswire on December 4, 2003. A copy is attached.

### 4. Summary of Material Change

On December 1, 2003, CME Telemetrix Inc. (“CME”) finalized an agreement to buy-back its glucose monitoring license from Motorola, Inc. (NYSE:MOT).

### 5. Full Description of Material Change

On December 1, 2003, CME Telemetrix Inc. (“CME”) finalized an agreement to buy-back its glucose monitoring license from Motorola, Inc. (NYSE:MOT).
CME plans to re-license its non-invasive glucose monitoring capability, as well as the capabilities it is developing to monitor other key analytes such as cholesterol and HbA1c. CME will now focus on securing a partner capable of transitioning its technology from development to commercialization, with a proven channel to market and a commitment to people suffering from diabetes.

### 6. Reliance on Confidentiality Provisions of Securities Legislation

Not applicable.

### 7. Omitted Information

No significant facts have been omitted from this report.

## 8. Senior Officer

For additional information with respect to this material change, please contact Mr. Duncan MacIntyre, Chief Executive Officer, (519) 886-8440.

## 9. Statement of Senior Officer

The foregoing accurately discloses the material change referred to herein.

DATED at Waterloo, Ontario, this 11th day of December, 2003.

*"Stephen Curtis"*
Stephen Curtis
Chief Financial Officer

www.cmetele.com www.equicomgroup.com

**FOR IMMEDIATE RELEASE** **TSX Venture: YME**

# CME TELEMETRIX REACQUIRES RIGHTS TO GLUCOSE MONITORING TECHNOLOGY

**WATERLOO, Ont. December 4, 2003 -- CME Telemetrix Inc. ("CME", TSX Venture: YME)**, a leading-edge developer of near-infrared instruments, today announced that it has completed the successful buy-back of its glucose monitoring license from Motorola, Inc. (NYSE:MOT).

"Once we were advised of Motorola's change of strategy to move away from life sciences, we initiated the lengthy process of negotiating back the rights to our glucose monitoring technology," said Mr. Rick Darnaby, Chairman of CME Telemetrix and former Motorola executive. "I believe this repatriation is timely given our current financing initiatives, and provides significant opportunity and value to CME and its shareholders."

CME plans to re-license its non-invasive glucose monitoring capability, as well as the capabilities it is developing to monitor other key analytes such as cholesterol and HbA1c. CME will now focus on securing a partner capable of transitioning its technology from development through commercialization, with a proven channel to market and a commitment to people suffering from diabetes.

"Our partnership with Motorola was very successful and productive; we depart with a vastly improved technology, a stronger patent position, and a board of directors that includes former senior Motorola executives dedicated to the success of CME," said Duncan Macintyre, President and CEO of CME Telemetrix. "Dr. George Maracas, a valuable architect in the building of Motorola's life sciences portfolio, has also joined CME as Chief Scientific Officer."

***About CME Telemetrix***

CME Telemetrix is a leading developer of optical based technologies. Through its expertise in optics, algorithms, and electronics, the Company has developed a platform technology with multiple commercial applications. Currently, the Company's primary focus is the development of a device that utilizes near infrared light for non-invasive blood analysis, particularly for measuring blood glucose levels for people with diabetes.

CME Telemetrix has entered into licensing agreements with several international companies, including Motorola, Inc, Johnson & Johnson, and ESE Inc. Sh ares of CME Telemetrix trade under the symbol YME on the TSX Venture Exchange.

Additional information is available on the Company's website at www.cmetele.com.

**For more information, please contact:**

Duncan MacIntyre
President & CEO
**CME Telemetrix Inc.**
519-886-8440
519-886-8442 Fax
E-mail: info@cmetele.com
Internet: www.cmetele.com

Jason Hogan
Investor Relations
**The Equicom Group Inc.**
416-815-0700 ext. 222
416-815-0080 Fax
E-mail: jhogan@equicomgroup.com
Internet: www.equicomgroup.com